Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Fuhong Hanlin: Clinical trial application for recombinant human hyaluronidase injection approved by the National Medical Products Administration
Fuhong Hanlin Announcement: Recently, the company’s independently developed HLXTE-HAase02 (recombinant human hyaluronidase injection) received approval from the National Medical Products Administration (NMPA) for its Phase I clinical trial application (IND). The company plans to conduct the relevant clinical trials within China (excluding Hong Kong, Macau, and Taiwan) once the conditions are met.